Prothena Stock Price, News & Analysis (NASDAQ:PRTA)

$38.12 0.16 (0.42 %)
(As of 12/14/2017 01:03 AM ET)
Previous Close$37.96
Today's Range$37.37 - $38.81
52-Week Range$37.37 - $70.00
Volume478,100 shs
Average Volume299,378 shs
Market Capitalization$1.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.42

About Prothena (NASDAQ:PRTA)

Prothena logoProthena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRTA
CUSIPN/A
Phone353-1236-2500

Debt

Debt-to-Equity RatioN/A
Current Ratio11.95%
Quick Ratio11.95%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.05 million
Price / Sales1,395.92
Cash FlowN/A
Price / CashN/A
Book Value$10.60 per share
Price / Book3.60

Profitability

Trailing EPS($4.23)
Net Income$-160,100,000.00
Net Margins-562.19%
Return on Equity-34.40%
Return on Assets-28.61%

Miscellaneous

Employees96
Outstanding Shares38,450,000

Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Corporation PLC (NASDAQ:PRTA) posted its earnings results on Tuesday, November, 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.41) by $0.04. The biotechnology company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.28 million. Prothena had a negative return on equity of 34.40% and a negative net margin of 562.19%. The company's revenue for the quarter was down 33.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.26) earnings per share. View Prothena's Earnings History.

When will Prothena make its next earnings announcement?

Prothena is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Prothena.

Where is Prothena's stock going? Where will Prothena's stock price be in 2017?

12 Wall Street analysts have issued 1-year target prices for Prothena's stock. Their forecasts range from $55.00 to $100.00. On average, they anticipate Prothena's stock price to reach $77.73 in the next twelve months. View Analyst Ratings for Prothena.

What are Wall Street analysts saying about Prothena stock?

Here are some recent quotes from research analysts about Prothena stock:

  • 1. Cantor Fitzgerald analysts commented, "Gotta be in it to win it. The logic behind impeding cell trafficking as a means treating T cell-mediated autoimmune disorders has been established with Tysabri in relapsing forms of MS, so the merits of pursuing non-CNS indications makes abundant sense to us." (9/28/2017)
  • 2. According to Zacks Investment Research, "The narrower-than-expected loss in the second quarter was encouraging. Prothena’s efforts on developing its pipeline are encouraging. The company's license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive. The collaboration not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. Prothena recently earned a $30 million of milestone payment from Roche. The company’s shares have outperformed the industry in the past one year. We expect investor focus to remain on further updates from its late-stage candidate, NEOD001. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates." (8/11/2017)
  • 3. Instinet analysts commented, "We are initiating on Prothena Corporation (PRTA) with a Buy rating and an $87 target price. We recommend owning PRTA shares ahead of Phase 2b PRONTO trial readout expected in early 2018 for lead asset NEOD001 in AL amyloidosis (a >$1.5bn peak sales opportunity). We view the pullback from 2016 highs and recent lows as an opportunity to accumulate the shares ahead of PRONTO data. Positive results from PRONTO based on change in NT-proBNP, a biomarker that NEOD001 substantially moved, yielding 53% responder rate in an early Phase 1/2b, are likely to support a conditional approval in the EU by 2019. In addition, we expect biomarker data from the PRX003 Phase 1b study to define mechanistically the breadth opportunity for MCAM/Th17-cell targeting in autoimmune disease, a potential multibillion dollar opportunity that, in our view, will raise the floor on PRTA's valuation. PRX002 could become a strong driver of PRTA's valuation in out years; however, given few near-term catalysts, it is unlikely to be a driver for PRTA shares in the next 12 months." (3/1/2017)

Who are some of Prothena's key competitors?

Who are Prothena's key executives?

Prothena's management team includes the folowing people:

  • Lars G. Ekman M.D., Ph.D., Independent Chairman of the Board (Age 67)
  • Gene G. Kinney Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Tran B. Nguyen, Chief Financial Officer (Age 43)
  • Karin L. Walker CPA, Chief Accounting Officer, Controller (Age 53)
  • Wagner Zago, Chief Scientific Officer
  • Arthur W. Homan, Chief Legal Officer (Age 57)
  • Carol D. Karp, Chief Regulatory Officer (Age 64)
  • Martin Koller M.D., Chief Medical Officer (Age 66)
  • Tara Nickerson Ph.D., Chief Business Officer (Age 44)
  • K. Anders O. Harfstrand M.D., Ph.D., Director (Age 60)

Who owns Prothena stock?

Prothena's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Woodford Investment Management Ltd (29.65%), Westfield Capital Management Co. LP (1.62%), Jennison Associates LLC (1.07%), Pinnacle Associates Ltd. (0.94%), Oak Ridge Investments LLC (0.75%) and Hood River Capital Management LLC (0.52%). Company insiders that own Prothena stock include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena.

Who sold Prothena stock? Who is selling Prothena stock?

Prothena's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Oak Ridge Investments LLC, Westfield Capital Management Co. LP, Woodford Investment Management Ltd, Nationwide Fund Advisors, Pinnacle Associates Ltd., California State Teachers Retirement System and Platinum Investment Management Ltd.. Company insiders that have sold Prothena company stock in the last year include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker and Tara Nickerson. View Insider Buying and Selling for Prothena.

Who bought Prothena stock? Who is buying Prothena stock?

Prothena's stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Sectoral Asset Management Inc, Westpac Banking Corp, Sphera Funds Management LTD., Schwab Charles Investment Management Inc., Parametrica Management Ltd, Hood River Capital Management LLC and Birchview Capital LP. View Insider Buying and Selling for Prothena.

How do I buy Prothena stock?

Shares of Prothena can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of Prothena stock can currently be purchased for approximately $38.12.

How big of a company is Prothena?

Prothena has a market capitalization of $1.54 billion and generates $1.05 million in revenue each year. The biotechnology company earns $-160,100,000.00 in net income (profit) each year or ($4.23) on an earnings per share basis. Prothena employs 96 workers across the globe.

How can I contact Prothena?

Prothena's mailing address is ADELPHI PLAZA UPPER GEORGE`S STREET, DUN LAOGHAIRE L2, A96 T927. The biotechnology company can be reached via phone at 353-1236-2500 or via email at [email protected]


MarketBeat Community Rating for Prothena (PRTA)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  444
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Prothena (NASDAQ:PRTA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.933.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $76.15$77.85$78.62$77.00
Price Target Upside: 60.93% upside41.46% upside25.30% upside36.94% upside

Prothena (NASDAQ:PRTA) Consensus Price Target History

Price Target History for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ:PRTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/4/2017OppenheimerSet Price TargetBuy$70.00HighView Rating Details
11/20/2017WedbushDowngradeOutperform -> Neutral$75.00 -> $55.00N/AView Rating Details
10/23/2017Deutsche BankSet Price TargetBuy$73.00N/AView Rating Details
10/2/2017Jefferies GroupReiterated RatingBuy$100.00LowView Rating Details
10/2/2017SunTrust BanksReiterated RatingBuy$75.00LowView Rating Details
9/29/2017Royal Bank of CanadaReiterated RatingBuyHighView Rating Details
9/29/2017BTIG ResearchLower Price TargetBuy -> Buy$80.00 -> $77.00HighView Rating Details
9/28/2017Cantor FitzgeraldReiterated RatingBuy$79.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$83.00HighView Rating Details
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$87.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/AView Rating Details
8/4/2016BarclaysBoost Price TargetOverweight$60.00 -> $70.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Prothena (NASDAQ:PRTA) Earnings History and Estimates Chart

Earnings by Quarter for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ PRTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018($1.47)N/AView Earnings Details
11/7/2017Q3($1.41)($1.37)$0.28 million$0.19 millionViewN/AView Earnings Details
8/8/20176/30/2017($0.89)($0.46)$16.08 million$26.81 millionViewN/AView Earnings Details
5/9/20173/31/2017($1.32)($0.99)$0.26 million$0.26 millionViewN/AView Earnings Details
2/14/2017Q416($1.12)($1.41)$5.35 million$0.20 millionViewListenView Earnings Details
11/1/2016Q3($1.22)($1.26)$0.49 million$0.29 millionViewN/AView Earnings Details
8/2/2016Q2($0.91)($1.18)$0.39 million$0.33 millionViewN/AView Earnings Details
5/3/2016Q116($0.77)($0.81)$0.27 million$0.27 millionViewN/AView Earnings Details
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details
11/2/2015($0.66)($0.73)$0.28 million$0.43 millionViewN/AView Earnings Details
8/4/2015Q2($0.56)($0.59)$0.60 million$0.28 millionViewN/AView Earnings Details
5/5/2015($0.59)($0.55)$1.95 million$0.59 millionViewN/AView Earnings Details
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details
8/4/2014Q214$0.06$15.17 million$15.12 millionViewN/AView Earnings Details
5/5/2014$0.81$0.78$30.17 million$32.23 millionViewN/AView Earnings Details
3/6/2014Q113($0.52)ViewN/AView Earnings Details
3/28/2013Q412($0.82)$0.13 million$0.58 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Prothena (NASDAQ:PRTA) Earnings Estimates

2017 EPS Consensus Estimate: ($4.96)
2018 EPS Consensus Estimate: ($5.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.42)($1.28)($1.36)
Q2 20174($1.20)($0.50)($0.87)
Q3 20174($1.54)($1.21)($1.36)
Q4 20174($1.45)($1.29)($1.38)
Q1 20182($1.49)($1.45)($1.47)
Q2 20182($1.60)($1.35)($1.48)
Q3 20182($1.55)($1.16)($1.36)
Q4 20182($1.61)($1.05)($1.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Prothena (NASDAQ:PRTA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Prothena (NASDAQ PRTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.10%
Insider Trades by Quarter for Prothena (NASDAQ:PRTA)
Institutional Ownership by Quarter for Prothena (NASDAQ:PRTA)

Prothena (NASDAQ PRTA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Dennis J SelkoeDirectorSell3,500$64.17$224,595.00View SEC Filing  
9/28/2017Christopher S HenneyDirectorSell900$70.00$63,000.00View SEC Filing  
9/28/2017Gene G KinneyInsiderSell2,800$70.00$196,000.00View SEC Filing  
9/27/2017Tara NickersonInsiderSell4,724$69.05$326,192.20View SEC Filing  
9/25/2017Tara NickersonInsiderSell17,500$63.60$1,113,000.00View SEC Filing  
7/17/2017Karin L WalkerInsiderSell5,000$64.89$324,450.00View SEC Filing  
7/7/2017Dennis J SelkoeDirectorSell3,500$58.11$203,385.00View SEC Filing  
4/17/2017Karin L WalkerInsiderSell5,000$52.25$261,250.00View SEC Filing  
4/3/2017Dennis J SelkoeDirectorSell3,500$55.86$195,510.00View SEC Filing  
3/9/2017Tran NguyenCFOBuy1,000$51.32$51,320.00View SEC Filing  
1/4/2017Arthur W HomanInsiderSell3,125$52.25$163,281.25View SEC Filing  
11/28/2016Dennis J SelkoeDirectorSell5,000$62.42$312,100.00View SEC Filing  
11/9/2016Gene G KinneyInsiderSell8,548$55.32$472,875.36View SEC Filing  
10/21/2016Gene G KinneyInsiderSell20,619$55.10$1,136,106.90View SEC Filing  
10/13/2016Karin L WalkerInsiderSell5,000$54.23$271,150.00View SEC Filing  
9/19/2016Karin L WalkerInsiderSell12,000$61.10$733,200.00View SEC Filing  
9/1/2016Arthur W HomanInsiderSell3,125$52.16$163,000.00View SEC Filing  
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.50View SEC Filing  
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.00View SEC Filing  
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.00View SEC Filing  
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.00View SEC Filing  
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.50View SEC Filing  
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00View SEC Filing  
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.00View SEC Filing  
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.25View SEC Filing  
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.00View SEC Filing  
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.00View SEC Filing  
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.00View SEC Filing  
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.00View SEC Filing  
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.00View SEC Filing  
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Prothena (NASDAQ PRTA) News Headlines

Source:
DateHeadline
ETFs with exposure to Prothena Corp. Plc : December 5, 2017ETFs with exposure to Prothena Corp. Plc : December 5, 2017
finance.yahoo.com - December 5 at 4:31 PM
Prothena (PRTA) Given a $70.00 Price Target by Oppenheimer AnalystsProthena (PRTA) Given a $70.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - December 4 at 10:16 AM
Prothena Corporation PLC (PRTA) Given Average Rating of "Buy" by BrokeragesProthena Corporation PLC (PRTA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 2 at 12:00 AM
Prothena Corp. Plc :PRTA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Prothena Corp. Plc :PRTA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 5:39 PM
Zacks: Brokerages Anticipate Prothena Corporation PLC (PRTA) Will Post Quarterly Sales of $270,000.00Zacks: Brokerages Anticipate Prothena Corporation PLC (PRTA) Will Post Quarterly Sales of $270,000.00
www.americanbankingnews.com - November 28 at 12:54 PM
Prothena Corporation PLC (PRTA) Expected to Announce Earnings of -$1.44 Per ShareProthena Corporation PLC (PRTA) Expected to Announce Earnings of -$1.44 Per Share
www.americanbankingnews.com - November 26 at 3:48 AM
Prothena Corporation plc: Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive ConferenceProthena Corporation plc: Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference
www.finanznachrichten.de - November 23 at 7:48 AM
Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive ConferenceProthena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 23 at 7:48 AM
Wedbush Weighs in on Prothena Corporation PLCs FY2017 Earnings (PRTA)Wedbush Weighs in on Prothena Corporation PLC's FY2017 Earnings (PRTA)
www.americanbankingnews.com - November 22 at 6:20 AM
Prothena Corporation PLC (PRTA) Lowered to "Neutral" at WedbushProthena Corporation PLC (PRTA) Lowered to "Neutral" at Wedbush
www.americanbankingnews.com - November 20 at 8:52 PM
Prothena is Now Oversold (PRTA)Prothena is Now Oversold (PRTA)
www.nasdaq.com - November 18 at 11:03 AM
Prothena Highlights Breadth of Novel Pipeline at R&D DayProthena Highlights Breadth of Novel Pipeline at R&D Day
finance.yahoo.com - November 18 at 11:03 AM
Prothena Corporation PLC Expected to Post FY2017 Earnings of ($4.23) Per Share (PRTA)Prothena Corporation PLC Expected to Post FY2017 Earnings of ($4.23) Per Share (PRTA)
www.americanbankingnews.com - November 13 at 2:34 AM
Jefferies Group Brokers Boost Earnings Estimates for Prothena Corporation PLC (PRTA)Jefferies Group Brokers Boost Earnings Estimates for Prothena Corporation PLC (PRTA)
www.americanbankingnews.com - November 10 at 1:54 PM
Prothena Corporation PLCs (PRTA) Buy Rating Reaffirmed at Oppenheimer Holdings, Inc.Prothena Corporation PLC's (PRTA) Buy Rating Reaffirmed at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 9 at 1:54 PM
Prothena Reports Third Quarter 2017 Financial Results and Provides R&D UpdateProthena Reports Third Quarter 2017 Financial Results and Provides R&D Update
finance.yahoo.com - November 9 at 11:57 AM
Prothena reports 3Q lossProthena reports 3Q loss
finance.yahoo.com - November 9 at 11:57 AM
Woodford-backed Prothena targeted by short seller KerrisdaleWoodford-backed Prothena targeted by short seller Kerrisdale
finance.yahoo.com - November 9 at 11:57 AM
$300,000.00 in Sales Expected for Prothena Corporation PLC (PRTA) This Quarter$300,000.00 in Sales Expected for Prothena Corporation PLC (PRTA) This Quarter
www.americanbankingnews.com - November 9 at 10:30 AM
Prothena Corporation PLC (PRTA) Issues  Earnings Results, Beats Estimates By $0.03 EPSProthena Corporation PLC (PRTA) Issues Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - November 7 at 6:34 PM
-$1.41 EPS Expected for Prothena Corporation PLC (PRTA) This Quarter-$1.41 EPS Expected for Prothena Corporation PLC (PRTA) This Quarter
www.americanbankingnews.com - November 7 at 9:42 AM
Prothena Corporation PLC (PRTA) Receives Consensus Recommendation of "Buy" from AnalystsProthena Corporation PLC (PRTA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 6 at 8:28 PM
Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : November 3, 2017Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : November 3, 2017
finance.yahoo.com - November 4 at 9:05 AM
Prothena to Participate in the Credit Suisse 26th Annual Healthcare ConferenceProthena to Participate in the Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - November 2 at 7:56 AM
Prothena Corporation PLC (PRTA) to Release Earnings on TuesdayProthena Corporation PLC (PRTA) to Release Earnings on Tuesday
www.americanbankingnews.com - November 1 at 10:49 AM
Whats in the Cards for Prothena (PRTA) in Q3 Earnings?What's in the Cards for Prothena (PRTA) in Q3 Earnings?
finance.yahoo.com - November 1 at 7:42 AM
What's in the Cards for Prothena (PRTA) in Q3 Earnings?What's in the Cards for Prothena (PRTA) in Q3 Earnings?
finance.yahoo.com - November 1 at 7:42 AM
Prothena to Report Third Quarter 2017 Financial Results on November 7Prothena to Report Third Quarter 2017 Financial Results on November 7
finance.yahoo.com - November 1 at 7:42 AM
Financial Comparison: Prothena Corporation PLC (PRTA) vs. Its CompetitorsFinancial Comparison: Prothena Corporation PLC (PRTA) vs. Its Competitors
www.americanbankingnews.com - October 27 at 11:26 PM
Deutsche Bank AG Reiterates $73.00 Price Target for Prothena Corporation PLC (PRTA)Deutsche Bank AG Reiterates $73.00 Price Target for Prothena Corporation PLC (PRTA)
www.americanbankingnews.com - October 23 at 11:20 PM
Prothena Corporation PLC (PRTA) to Release Earnings on MondayProthena Corporation PLC (PRTA) to Release Earnings on Monday
www.americanbankingnews.com - October 23 at 11:18 AM
 Analysts Anticipate Prothena Corporation PLC (PRTA) Will Announce Quarterly Sales of $440,000.00 Analysts Anticipate Prothena Corporation PLC (PRTA) Will Announce Quarterly Sales of $440,000.00
www.americanbankingnews.com - October 20 at 5:14 AM
 Analysts Anticipate Prothena Corporation PLC (PRTA) Will Post Earnings of -$1.38 Per Share Analysts Anticipate Prothena Corporation PLC (PRTA) Will Post Earnings of -$1.38 Per Share
www.americanbankingnews.com - October 18 at 4:22 PM
Commit To Buy Prothena Corp At $40, Earn 10.2% Annualized Using OptionsCommit To Buy Prothena Corp At $40, Earn 10.2% Annualized Using Options
www.nasdaq.com - October 17 at 4:15 PM
Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : October 16, 2017Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : October 16, 2017
finance.yahoo.com - October 17 at 6:28 AM
Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : October 16, 2017Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : October 16, 2017
finance.yahoo.com - October 17 at 6:28 AM
Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : October 13, 2017Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : October 13, 2017
finance.yahoo.com - October 14 at 6:56 AM
Prothena Corporation PLC (PRTA) Given Consensus Rating of "Buy" by BrokeragesProthena Corporation PLC (PRTA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 6:56 PM
Short Interest Moves 24.5% Lower For PRTAShort Interest Moves 24.5% Lower For PRTA
www.thestreet.com - October 12 at 8:30 AM
Prothena Corporation PLC (PRTA) Rating Lowered to Sell at ValuEngineProthena Corporation PLC (PRTA) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - October 7 at 10:34 PM
Reviewing Prothena Corporation PLC (PRTA) and Versartis (VSAR)Reviewing Prothena Corporation PLC (PRTA) and Versartis (VSAR)
www.americanbankingnews.com - October 7 at 6:28 PM
Prothena Co. PLC (PRTA) Director Dennis J. Selkoe Sells 3,500 SharesProthena Co. PLC (PRTA) Director Dennis J. Selkoe Sells 3,500 Shares
www.americanbankingnews.com - October 4 at 8:02 PM
FY2017 EPS Estimates for Prothena Co. PLC Lifted by Analyst (PRTA)FY2017 EPS Estimates for Prothena Co. PLC Lifted by Analyst (PRTA)
www.americanbankingnews.com - October 4 at 8:42 AM
Head to Head Contrast: PTC Therapeutics (PTCT) & Prothena Corporation PLC (PRTA)Head to Head Contrast: PTC Therapeutics (PTCT) & Prothena Corporation PLC (PRTA)
www.americanbankingnews.com - October 3 at 10:22 PM
Prothenas Psoriasis Candidate Disappoints in Phase I Study - NasdaqProthena's Psoriasis Candidate Disappoints in Phase I Study - Nasdaq
www.nasdaq.com - October 3 at 11:06 AM
Prothena's Psoriasis Candidate Disappoints in Phase I StudyProthena's Psoriasis Candidate Disappoints in Phase I Study
finance.yahoo.com - October 3 at 11:06 AM
Prothena Corporation PLC (PRTA) Stock Rating Reaffirmed by Deutsche Bank AGProthena Corporation PLC (PRTA) Stock Rating Reaffirmed by Deutsche Bank AG
www.americanbankingnews.com - October 2 at 3:14 PM
Prothena Corporation PLC (PRTA) Rating Reiterated by Jefferies Group LLCProthena Corporation PLC (PRTA) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 2 at 1:20 PM
Prothena Corporation PLC (PRTA) Earns Buy Rating from SunTrust Banks, Inc.Prothena Corporation PLC (PRTA) Earns Buy Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - October 2 at 1:20 PM
-$1.38 EPS Expected for Prothena Corporation PLC (PRTA) This Quarter-$1.38 EPS Expected for Prothena Corporation PLC (PRTA) This Quarter
www.americanbankingnews.com - September 29 at 10:08 PM

SEC Filings

Prothena (NASDAQ:PRTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Prothena (NASDAQ:PRTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Prothena (NASDAQ PRTA) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.